Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dostarlimab + Chemoradiation for Stage IIIC Endometrial Cancer
NCT05819892Phase 1Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2023
- Primary completion
- Mar 2027
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label trial of dostarlimab in endometrial cancer (EC) (3 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Incidence of Adverse Events. Started Jul 2023; status: recruiting.
02
Drugs
dostarlimab
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT05819892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05819892.